Anaveon Announces Presentation of Positive ANV600 Clinical Data at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio

Anaveon Presents Positive ANV600 Phase 1 Data at ASCO 2026

Anaveon announced new clinical data for its legacy oncology asset ANV600 (sunekafusp alpha) from the EXPAND-1 Phase 1 study, which will be presented at the 2026 ASCO Annual Meeting. The data demonstrated a manageable safety profile as monotherapy and in combination with pembrolizumab, clear proof-of-mechanism showing preferential proliferation of PD-1+ CD8+ T cells, and encouraging early clinical activity including tumor shrinkage and durable benefit in patients with advanced solid tumors. Following a strategic pivot to immunology, Anaveon is actively seeking global development and commercialization partners for its oncology portfolio, with a recommended Phase 2 dose for ANV600 already established.

• The EXPAND-1 Phase 1 study demonstrated a manageable safety profile for ANV600 both as a monotherapy and when combined with pembrolizumab. Crucially, the study provided clear proof-of-mechanism, showing preferential proliferation of PD-1+ CD8+ T cells over regulatory T cells. This indicates ANV600's ability to selectively expand tumor-reactive T cells, aligning with its design as a non-blocking PD-1-targeted IL-2R-βγ agonist aimed at reducing toxicities associated with traditional IL-2 therapy.
• Encouraging early clinical activity was observed, including tumor shrinkage in a meaningful proportion of patients with advanced solid tumors. This activity was seen in both post-CPI (checkpoint inhibitor) and CPI-naïve settings, suggesting broad potential. Patients also experienced disease control and durable benefit, reinforcing the therapeutic promise of ANV600, particularly for those who may be resistant or relapsed after existing checkpoint inhibitor treatments.
• Anaveon is actively seeking global development and commercialization partners for its oncology portfolio, including ANV600, following a strategic pivot to immunology. The company believes ANV600 is ideally suited for a partner with resources and expertise to advance it into Phase 2 development, particularly in CPI-resistant NSCLC and other immuno-oncology indications. A recommended Phase 2 dose has already been established, streamlining the path forward for potential collaborators.

Addressing Unmet Needs in CPI-Resistant Advanced Solid Tumors

Recent research has identified several critical patient populations with advanced solid tumors that remain inadequately served by current therapeutic approaches. These unmet needs span across vulnerable patient demographics, treatment-resistant disease states, and optimization opportunities for existing therapies.

• Elderly patients (≥75 years) face limited evidence-based treatment options, with the PRaG 9.0 Study representing a pioneering effort to evaluate immunotherapy efficacy and safety in this population through a combination of PD-1/PD-L1 inhibitors, radiotherapy, and GM-CSF

• Frail patients with advanced cancer experience substantial toxicities even with modern treatments, requiring more individualized and ethically grounded approaches that integrate geriatric and palliative assessments with improved shared decision-making processes

• Patients with immunotherapy-refractory tumors represent a significant unmet need, particularly those with tumor microenvironments rich in immunosuppressive M2-like macrophages that suppress adaptive immunity and promote disease progression

• Patients with exhausted treatment options demonstrate a critical gap between genomic profiling (87% of patients) and actionable target identification (57%) versus actual targeted therapy utilization (only 24% of patients with actionable targets received matched treatment)

• Long-term responders to immunotherapy or targeted therapy experience unique psychosocial challenges, living in a "twilight zone" where they neither feel like patients nor completely healthy, requiring tailored support and potentially adjusted monitoring frequencies

• Patients requiring comprehensive biomarker testing remain underserved with only 35% receiving guideline-recommended testing, despite associations between lack of testing and worsened clinical outcomes including overall survival

• Patients with high baseline tumor size show significantly worse survival outcomes when receiving biomarker-matched targeted therapy (OS: 16.6 vs. 8.2 months for low vs. high tumor burden), indicating need for enhanced therapeutic strategies in high-burden disease

ANV600: A Targeted IL-2 Strategy for Enhanced Immuno-Oncology

The recent data for ANV600 underscore a significant step forward in the pursuit of more effective and safer immuno-oncology strategies. This novel bispecific antibody-cytokine fusion protein is engineered to deliver IL-2Rβγ agonism directly to PD-1+ T cells, a design that critically avoids the systemic toxicities and unwanted Treg expansion often associated with conventional IL-2 therapies. By targeting a non-blocking epitope on PD-1, ANV600 maintains compatibility with established PD-1 checkpoint inhibitors, offering a compelling approach to enhance anti-tumor immunity.

The Phase 1 EXPAND-1 study results are particularly encouraging, demonstrating a manageable safety profile both as monotherapy and in combination with pembrolizumab. Crucially, the data confirmed the intended proof-of-mechanism, showing preferential proliferation of PD-1+ CD8+ T cells, alongside early signs of clinical activity including tumor shrinkage and durable benefit in patients with advanced solid tumors. This validation of its unique mechanism in a clinical setting positions ANV600 as a potentially transformative asset.

For Anaveon, this data package, coupled with an established recommended Phase 2 dose, makes ANV600 an attractive proposition for potential global development and commercialization partners. The strategic implications are clear:

• A Differentiated Immuno-Oncology Asset: ANV600 offers a unique mechanism to selectively boost tumor-specific T cell responses, providing a competitive edge in a crowded market.

• Enhanced Checkpoint Inhibitor Efficacy: Its additive effects with PD-1 inhibitors could expand the utility of existing therapies, potentially benefiting patients who are resistant or have progressed on current checkpoint blockade.

However, several risks warrant careful consideration. The promising early clinical activity must be rigorously validated in larger, later-stage trials to confirm long-term efficacy and durability across diverse patient populations. Furthermore, the highly competitive immuno-oncology landscape demands that ANV600 demonstrate clear superiority or a distinct advantage to achieve significant market penetration. Finally, the inherent complexity of manufacturing a bispecific antibody-cytokine fusion protein could pose commercialization challenges. Despite these considerations, ANV600 represents a sophisticated approach to harnessing the power of IL-2 in a targeted manner, holding promise for a new generation of cancer immunotherapies.